INTRODUCTION AND HYPOTHESIS: This study deals with assessment of safety, efficacy, and potential complications of Prolift+M system to correct uterovaginal prolapse. METHODS: We analyzed a prospective cohort treated with the Gynecare PROLIFT+M mesh system between October 2008 and March 2010. A composite score that included subjective/objective cure and lack of complications was used to assess treatment success. RESULTS: One hundred sixty-seven women (age 65.1 ± 11.2 years, BMI 29.2 ± 5.8 kg/m(2)) were treated for pelvic organ prolapse using the PROLIFT+M system. Seven anterior Prolift+M, 42 posterior Prolift+M, and 118 total Prolift+M mesh surgeries were performed in patients with stage II or greater degrees of prolapse. Mean operative time was 122.7 ± 43.9 min. Mean intraoperative blood loss was 119.4 ± 125.3 ml. Our composite success score was 72.5% (treatment failures per POP-Q stage 1.4%, perception of bulge 4.4%, erosions 3.6%, pain/dyspareunia 3.7%, incontinence 0.7%, de novo urge urinary incontinence 8.7%, voiding dysfunction 0.6%, recurrent urinary tract infection 2.2%, and anal incontinence 2.2%). CONCLUSIONS: Prolift+M surgery is safe and effective with minimal postoperative morbidities.
INTRODUCTION AND HYPOTHESIS: This study deals with assessment of safety, efficacy, and potential complications of Prolift+M system to correct uterovaginal prolapse. METHODS: We analyzed a prospective cohort treated with the Gynecare PROLIFT+M mesh system between October 2008 and March 2010. A composite score that included subjective/objective cure and lack of complications was used to assess treatment success. RESULTS: One hundred sixty-seven women (age 65.1 ± 11.2 years, BMI 29.2 ± 5.8 kg/m(2)) were treated for pelvic organ prolapse using the PROLIFT+M system. Seven anterior Prolift+M, 42 posterior Prolift+M, and 118 total Prolift+M mesh surgeries were performed in patients with stage II or greater degrees of prolapse. Mean operative time was 122.7 ± 43.9 min. Mean intraoperative blood loss was 119.4 ± 125.3 ml. Our composite success score was 72.5% (treatment failures per POP-Q stage 1.4%, perception of bulge 4.4%, erosions 3.6%, pain/dyspareunia 3.7%, incontinence 0.7%, de novo urge urinary incontinence 8.7%, voiding dysfunction 0.6%, recurrent urinary tract infection 2.2%, and anal incontinence 2.2%). CONCLUSIONS: Prolift+M surgery is safe and effective with minimal postoperative morbidities.
Authors: R C Bump; A Mattiasson; K Bø; L P Brubaker; J O DeLancey; P Klarskov; B L Shull; A R Smith Journal: Am J Obstet Gynecol Date: 1996-07 Impact factor: 8.661
Authors: P Debodinance; J Berrocal; H Clavé; M Cosson; O Garbin; B Jacquetin; C Rosenthal; D Salet-Lizée; R Villet Journal: J Gynecol Obstet Biol Reprod (Paris) Date: 2004-11
Authors: Reijo Hiltunen; Kari Nieminen; Teuvo Takala; Eila Heiskanen; Mauri Merikari; Kirsti Niemi; Pentti K Heinonen Journal: Obstet Gynecol Date: 2007-08 Impact factor: 7.661
Authors: Fréderic Caquant; Pierre Collinet; Philippe Debodinance; Juan Berrocal; Olivier Garbin; Claude Rosenthal; Henri Clave; Richard Villet; Bernard Jacquetin; Michel Cosson Journal: J Obstet Gynaecol Res Date: 2008-08 Impact factor: 1.730